This is an expanded access program (EAP) for Inotersen for patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy.

Trial Profile

This is an expanded access program (EAP) for Inotersen for patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy.

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 27 Oct 2017 According to Ionis Pharmaceuticals media release, the expanded access program (EAP) is palnned to initiate in recent coming months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top